Cargando…
Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
Autores principales: | Louveau, Baptiste, Tost, Jörg, Mauger, Florence, Sadoux, Aurélie, Podgorniak, Marie-Pierre, How-Kit, Alexandre, Pages, Cécile, Roux, Jennifer, Da Meda, Laetitia, Lebbe, Céleste, Mourah, Samia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
ESMO Open
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519801/ https://www.ncbi.nlm.nih.gov/pubmed/28761746 http://dx.doi.org/10.1136/esmoopen-2017-000173 |
Ejemplares similares
-
Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
por: Louveau, Baptiste, et al.
Publicado: (2019) -
Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019) -
A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors
por: Louveau, Baptiste, et al.
Publicado: (2019) -
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023) -
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)